New presentations of Viread launched and licence extended for use in younger patients

The nucleotide analogue tenofovir (Viread) has been licensed for use in young children with HIV infection and adolescents with hepatitis B.

Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY
Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY

Viread can now be prescribed, in combination with other antiretrovirals, for children aged 2 years and older with HIV-1 infection. In addition, it may be used to treat chronic hepatitis B in adolescents aged 12 years and older with compensated liver disease, evidence of active viral replication, persistently elevated ALT levels and histological evidence of active inflammation and/or fibrosis.

New tablets and granules now available

In order to support dosing in children aged 6–12 years, Gilead has launched three new strengths of Viread tablets: 123mg (for children 17–22kg); 163mg (for children 22–28kg); and 204mg (for children 28–55kg). An oral granule formulation is also now available for children aged 2–6 years and for patients of all ages when a solid dosage form is not appropriate. The granules should be mixed with soft food (eg, yoghurt) before being taken.

Discontinue if renal dysfunction develops in children

Tenofovir is not recommended for use in children with renal impairment and should be discontinued in children who develop renal impairment.

View Viread drug records

Further information: Gilead Sciences

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Stribild: a combined four-drug once-daily treatment for HIV

Stribild: a combined four-drug once-daily treatment for HIV

Stribild is a combination tablet containing elvitegravir,...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more